☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - August 2012

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2012 (PDF).

This update contains drug safety information informing clinicians that all intra-nasal formulations of calcitonin (Miacalcic®) are being withdrawn because of an increased risk of cancer associated with the long-term use. These products are licensed for use in osteoporosis; the injectable products will remain available for short term use in conditions such as Paget’s disease and hypercalcaemia in malignancy.

The stop press section contains updated advice on drug interactions associated with simvastatin. Analysis of data from clinical trials and post-marketing surveillance has been used to update the recommended contra-indications and cautions.

  • Simvastatin is now contraindicated with ciclosporin, danazol and gemfibrozil
  • The maximum recommended dose for simvastatin in conjunction with amlodipine or diltiazem is now 20 mg per day

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - August 2012' by emailShare 'Drug Safety Update - August 2012' on FacebookShare 'Drug Safety Update - August 2012' on TwitterShare 'Drug Safety Update - August 2012' on LinkedInShare 'Drug Safety Update - August 2012' on reddit


One Comment to “Drug Safety Update - August 2012”

  1. [...] hot topic section contains a summary of the evidence that supports the recent advice to restrict the daily dose of simvastatin when used in conjunction with amlodipine or diltiazem. It [...]

    Pingback by Prescribing Advice for GPs » Drug Safety Update – October 2012 — October 31, 2012 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.